Der RANK/RANKL/OPG-Signalweg spielt eine wesentliche Rolle für die ossäre
Metastasierung des Prostatakarzinoms. Vorausgehende Studien konnten zeigen, dass …

Receptor activator of NF-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) are
key regulators of bone metabolism under both normal and pathological conditions, including …

BACKGROUND Late‐stage prostate cancer patients are refractory to hormone therapy and
exhibit a high propensity to develop skeletal metastasis. In this regard, the role of a novel …

OBJECTIVES The receptor activator of the NF‐kB ligand (RANKL) pathway is a key mediator
of prostate cancer (PC)‐induced bone disease. However, little is known about this pathway …

BACKGROUND Metastases to bone are a frequent complication of human prostate cancer
and result in the development of osteoblastic lesions that include an underlying osteoclastic …

Background The cytokine system RANKL (receptor activator of NF-κ B ligand), its receptor
RANK and the antagonist OPG (osteoprotegerin) play a critical role in bone turnover. Our …

The receptor activator of NF-kB (RANK) signalling pathway represents a promising target for
the therapy of bone-related tumours. In the present study we evaluated the impact of the …

We reported (PLoS One 6 (12): e28670, 2011) that the activation of c-Met signaling in
RANKL-overexpressing bone metastatic LNCaP cell and xenograft models increased …

The osteolytic nature of bone metastasis results from a tumor-driven increased bone
resorption. Bone remodeling is orchestrated by the molecular triad RANK-RANKL-OPG. This …

This study focused on the role of RANKL in prostate cancer EMT progression and
metastasis. Activation of RANK, a receptor activator of NF-kB, by its ligand RANKL, in a …